Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female \> 40 years of age.~* Pt with expected stay in hospital 6 days or \>, with expectation to be bedridden for \> 4 days.~* Pts admitted to the MICU, Regional Heart Units of LV-MHC~Exclusion Criteria:~* Surgical primary admission diagnosis~* Recent surgery within the past 12 weeks~* Planned surgery on the current admission~* Pregnancy~* Vent-dependent respiratory failure requiring intubation for \>24 hours.~* Known current DVT or PE prior to enrollment in study.~* Creatinine clearance \< 30 mL/min (calculated by the Cockcroft-Gault method) in a well-hydrated patient.~* Hx of prior or current lower upper or lower GI bleed.~* Platelet count \< 100,000 per cubic millimeter~* Current or prior anticoagulation within the prior 48 hours, excluding a single dose \&lor 24 hour period of prophylactic agent~* Bacterial endocarditis.~* Hemophilia~* Hypersensitivity to aspirin.~* Hypersensitivity to Arixtra or Lovenox~* Hx of hemorrhagic or ischemic stroke \< 3 months prior to enrolling~* Hematocrit \< 28%.~* SBP \>200 mmHg or DBP \>120 mmHg~* Positive for occult blood in stool.~* Admission to hospital for \> 48 hours prior to randomization~* Documented congenital or acquired bleeding disorder~* Indwelling intrathecal or epidural catheter~* Life expectancy \< 30 days~* Inability to have a flu assessment post-discharge from the hospital

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arixtra (Fondaparinox) 2.5 mg SC Daily (Type: ACTIVE_COMPARATOR): Arixtra (Fondaparinox) 2.5 mg SC Daily
- Lovenox 40mg SC Daily (Type: ACTIVE_COMPARATOR): Lovenox 40mg SC Daily

Based on this trial design, predict the completion outcome and termination type (if applicable).